- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PROTAGENIC THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mo | Protagenic Therapeutics wechselt nach NASDAQ-Delisting in den OTC-Handel | 5 | Investing.com Deutsch | ||
| Mo | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 1 | SEC Filings | ||
| 09.12.25 | Protagenic Therapeutics, Inc.: Results from Phase 1 Multiple-Dose Study of PT00114 | 306 | ACCESS Newswire | Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions NEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / Protagenic... ► Artikel lesen | |
| 27.11.25 | Protagenic Therapeutics receives Nasdaq non-compliance letter | 5 | Seeking Alpha | ||
| 27.11.25 | Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice | 325 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications... ► Artikel lesen | |
| 26.11.25 | Protagenic Therapeutics, Inc.\new - 10-Q, Quarterly Report | - | SEC Filings | ||
| 26.11.25 | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 14.11.25 | Protagenic Therapeutics, Inc.\new - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | - | SEC Filings | ||
| 13.11.25 | Protagenic-Aktie steigt nach Abschluss der Phase-1-Dosierung | 2 | Investing.com Deutsch | ||
| 13.11.25 | Protagenic schließt Dosierungsphase in Phase-1-Studie für Medikament gegen Stresserkrankungen ab | 2 | Investing.com Deutsch | ||
| 13.11.25 | Protagenic completes dosing in phase 1 study of stress disorder drug | 2 | Investing.com | ||
| 13.11.25 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study | 229 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / November 13, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel therapeutics for stress-related neuropsychiatric and... ► Artikel lesen | |
| 31.10.25 | Protagenic Therapeutics reicht Klage zur Rückabwicklung der Übernahme von Phytanix Bio ein | 2 | Investing.com Deutsch | ||
| 31.10.25 | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 2 | SEC Filings | ||
| 22.08.25 | Protagenic Therapeutics provides update on Form 10-Q filing timeline and Nasdaq compliance | 1 | Seeking Alpha | ||
| 22.08.25 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance | 496 | ACCESS Newswire | Delay Attributable to Merger-Related Financial Consolidation NEW YORK, NY / ACCESS Newswire / August 22, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX), a biopharmaceutical company developing novel... ► Artikel lesen | |
| 22.08.25 | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 4 | SEC Filings | ||
| 21.08.25 | Protagenic Therapeutics stock soars after advancing PT00114 to multiple-dose trial | 7 | Investing.com | ||
| 21.08.25 | Protagenic Therapeutics: Aktie schießt nach Meilenstein bei klinischer Studie in die Höhe | 6 | Investing.com Deutsch | ||
| 21.08.25 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders | 365 | ACCESS Newswire | Dosing Completion Expected by End of August; Phase 2 Trial Expected to Begin in 1Q 2026 NEW YORK, NY / ACCESS Newswire / August 21, 2025 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,027 | -9,33 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| CUREVAC | 3,930 | -0,05 % | XFRA 5CV: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCUREVAC N.V. O.N.... ► Artikel lesen | |
| VALNEVA | 4,170 | -0,19 % | Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement | Saint-Herblain (France), Pune, (India), December 31, 2025 - Valneva SE ("Valneva" or "the Company"), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company... ► Artikel lesen | |
| BIOFRONTERA | 2,450 | -3,16 % | PTA-news: Biofrontera AG: Biofrontera berichtet über die Ergebnisse der ersten neun Monate des Jahres 2025 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DER ERSTEN NEUN MONATE DES JAHRES 2025
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 17,580 | -9,29 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,380 | +0,73 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,379 | -1,20 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,400 | -0,81 % | Viking Therapeutics-Aktie: Hopp oder top? | Die Aktie von Viking Therapeutics steht exemplarisch für die enorme Dynamik im Markt für Abnehmmedikamente und spiegelt zugleich die noch ungelösten Bewertungsfragen im Biotech-Sektor wider. Trotz deutlicher... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| EDITAS MEDICINE | 1,844 | +0,49 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| VAXART | 0,270 | -0,74 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen | |
| MICROBOT MEDICAL | 1,796 | -1,70 % | Microbot Medical Inc.: Microbot Medical Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio | Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing... ► Artikel lesen | |
| IMMUNITYBIO | 1,790 | -2,48 % | ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ-A First in Europe | ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, to receive a positive recommendation... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | NSE - Affimed N.V. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities |
PROTAGENIC THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,560 (-43,08 %) liegt der Kurs bei 0,740 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROTAGENIC THERAPEUTICS INC finden Sie auf Wallstreet Online.